Cadence Pharmaceuticals, (FRA:QEW) EBITDA Margin % : -7.38% (As of Dec. 2013)

View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cadence Pharmaceuticals,'s EBITDA for the three months ended in Dec. 2013 was €-1.90 Mil. Cadence Pharmaceuticals,'s Revenue for the three months ended in Dec. 2013 was €25.78 Mil. Therefore, Cadence Pharmaceuticals,'s EBITDA margin for the quarter that ended in Dec. 2013 was -7.38%.

Cadence Pharmaceuticals, EBITDA Margin % Historical Data

The historical data trend for Cadence Pharmaceuticals,'s EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, EBITDA Margin % Chart

Cadence Pharmaceuticals, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

EBITDA Margin %

Get a 7-Day Free Trial

-511.26

-146.70

-16.23

Cadence Pharmaceuticals, Quarterly Data
	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13
EBITDA Margin %	Get a 7-Day Free Trial															-114.32	0.69	-42.26	-18.92	-7.38

Competitive Comparison of Cadence Pharmaceuticals,'s EBITDA Margin %

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cadence Pharmaceuticals,'s EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s EBITDA Margin % falls into.

Cadence Pharmaceuticals, EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cadence Pharmaceuticals,'s EBITDA Margin % for the fiscal year that ended in Dec. 2013 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2013 )	/	Revenue (A: Dec. 2013 )
	=	-13.338	/	82.166
	=	-16.23 %

Cadence Pharmaceuticals,'s EBITDA Margin % for the quarter that ended in Dec. 2013 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2013 )	/	Revenue (Q: Dec. 2013 )
	=	-1.902	/	25.778
	=	-7.38 %

Cadence Pharmaceuticals, (FRA:QEW) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Cadence Pharmaceuticals, EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadence Pharmaceuticals, (FRA:QEW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cadencepharm.com

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines